Related Experiment Video
Updated: Aug 25, 2026

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's
B Lemieux1, S Tartas, C Traulle
1Haematology Department, Centre Hospitalier Lyon Sud, Hospices civils de Lyon - Université Claude Bernard, Pierre-Benite, France.
Abstract:
Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...